Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma.

ABSTRACT:

Objective

This is a prospective, single-arm, phase Ib study to evaluate the safety and efficacy of camrelizumab combined with chemotherapy and apatinib as neoadjuvant therapy for locally advanced thoracic esophageal squamous cell carcinoma (ESCC).

Methods

The regimen encompassed 2-4 cycles of neoadjuvant camrelizumab, nab-paclitaxel, nedaplatin, and apatinib to treatment-naive patients with resectable locally advanced ESCC. The treatment was repeated every 14 days. Initially, six patients were planned to receive two cycles of neoadjuvant therapy as safety assessment, and then 24 patients received four cycles of neoadjuvant therapy, followed by esophagectomy after 4-8 weeks. The primary endpoint was safety. The key secondary endpoints were pathologic complete response (pCR) a

SUBMITTER: Wang Z 

PROVIDER: S-EPMC11256696 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature